Our findings provide evidence for further clinical investigation of the potential sensitivity of RAC1-amplified and RAC1-A159V-mutant HNSCC to Rac inhibitors, when such inhibitors become clinically available for human trials. The gene discussed is AKT1; the disease is head and neck squamous cell carcinoma.